Targeting the TLR-4/NF-κB axis and NLRP3 inflammasome presents a potential therapeutic strategy to mitigate inflammation and prevent DCM progression in diabetic patients [53,54]. This evidence concerns the gene NFKB1 and familial dilated cardiomyopathy.